Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 332 participants.
Also called NCT07276282
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 332 participants
- Registry
-
NCT07276282 -
2024-520364-34-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Switzerland
- Registry status
- Recruiting
Technical summary
Registry record NCT07276282. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-19 (actual); primary completion 2028-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
- Acronym
- ZEPHYR
- Condition
- Coronary Artery Disease
- Condition
- Acute Myocardial Infarction (AMI)
- Condition
- Coronary Atherosclerosis of Native Coronary Artery
- Intervention (Drug)
- Ziltivekimab
- Intervention (Drug)
- Placebo
- Lead sponsor
- ECRI bv
- Collaborator
- Novo Nordisk A/S
- Collaborator
- Insel Gruppe AG, University Hospital Bern
- Collaborator
- Cardialysis B.V.
Record details
- Record id
cardio:ct-nct07276282- Content hash
94f126083b5de0f7abb8ecef3f5051e7cba49f3a53376f38f643c85fb4688fb1